Exchange Traded Concepts
BMY icon

Exchange Traded Concepts’s Bristol-Myers Squibb BMY Stock Holding History

Exchange Traded Concepts’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$56.9M Buy
911,319
+261,753
+40% +$16.5M 0.23% 76
2026
Q2 		$37.4M Buy
649,566
+88,948
+16% +$5.11M 0.17% 109
2026
Q1 		$34M Buy
560,618
+444,385
+382% +$25.9M 0.24% 85
2025
Q4 		$6.27M Sell
116,233
-523,740
-82% -$25.2M 0.05% 351
2025
Q3 		$28.9M Buy
639,973
+83,214
+15% +$3.89M 0.25% 81
2025
Q2 		$25.8M Buy
556,759
+536,879
+2,701% +$26.4M 0.32% 74
2025
Q1 		$1.21M Sell
19,880
-2,703
-12% -$158K 0.02% 502
2024
Q4 		$1.28M Sell
22,583
-3,885
-15% -$217K 0.03% 488
2024
Q3 		$1.37M Buy
26,468
+4,064
+18% +$191K 0.03% 427
2024
Q2 		$930K Sell
22,404
-185
-0.8% -$8.28K 0.02% 457
2024
Q1 		$1.23M Sell
22,589
-6,001
-21% -$306K 0.03% 396
2023
Q4 		$1.47M Sell
28,590
-341,185
-92% -$17.9M 0.04% 325
2023
Q3 		$21.5M Buy
369,775
+197,106
+114% +$12.1M 0.61% 29
2023
Q2 		$11M Buy
172,669
+51,682
+43% +$3.47M 0.27% 98
2023
Q1 		$8.39M Sell
120,987
-62,016
-34% -$4.37M 0.23% 87
2022
Q4 		$13.2M Sell
183,003
-6,123
-3% -$462K 0.38% 53
2022
Q3 		$13.4M Buy
189,126
+86,011
+83% +$6.24M 0.44% 17
2022
Q2 		$7.94M Sell
103,115
-7,542
-7% -$574K 0.23% 62
2022
Q1 		$8.08M Buy
110,657
+68,396
+162% +$4.59M 0.16% 78
2021
Q4 		$2.64M Sell
42,261
-217,899
-84% -$12.8M 0.05% 217
2021
Q3 		$15.4M Buy
260,160
+101,055
+64% +$6.66M 0.39% 32
2021
Q2 		$10.6M Buy
159,105
+43,840
+38% +$2.86M 0.34% 52
2021
Q1 		$7.28M Sell
115,265
-8,975
-7% -$558K 0.27% 61
2020
Q4 		$7.71M Buy
124,240
+116,713
+1,551% +$7.18M 0.36% 43
2020
Q3 		$454K Buy
7,527
+3,667
+95% +$221K 0.03% 321
2020
Q2 		$227K Sell
3,860
-37,482
-91% -$2.24M 0.04% 448
2020
Q1 		$2.3M Buy
41,342
+29,731
+256% +$1.82M 1.25% 7
2019
Q4 		$745K Buy
+11,611
New +$665K 0.16% 72

Other funds holding BMY

Pzena Investment Management
Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Exchange Traded Concepts's BMY Position: Q3 2026 in Review

Exchange Traded Concepts increased its Bristol-Myers Squibb (BMY) stake by 40% in Q3 2026, buying an estimated $16.5M and bringing the position to 911,319 shares worth $56.9M. The position accounts for 0.23% of the portfolio, ranked #76.

Exchange Traded Concepts first reported a position in BMY in Q4 2019 and has held it in 28 quarters since. 1,125 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Exchange Traded Concepts held 911,319 shares of Bristol-Myers Squibb worth $56.9M as of Q3 2026.
  • Exchange Traded Concepts bought 261,753 Bristol-Myers Squibb shares in Q3 2026, an estimated $16.5M.
  • Bristol-Myers Squibb made up 0.23% of Exchange Traded Concepts's portfolio in Q3 2026, its #76 holding.
  • Exchange Traded Concepts first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 28 quarters since.
  • 1,125 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Exchange Traded Concepts's 13F filing for Q3 2026, filed 28 Oct 2026.